Hoth Therapeutics Past Earnings Performance
Past criteria checks 0/6
Hoth Therapeutics's earnings have been declining at an average annual rate of -1.2%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually.
Key information
-1.2%
Earnings growth rate
37.0%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | n/a |
Return on equity | -100.2% |
Net Margin | n/a |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury
Sep 20Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule
Jun 29Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation
Nov 12Hoth Therapeutics extends agreement for experimental antibiotic
Jun 18We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate
Jun 10Hoth Therapeutics expands research agreement with VCU for COVID-19 therapeutic
May 05Hoth Therapeutics shares rise 10% on developmental plans for HT-KIT in multiple orphan diseases and rare cancers
May 03Hoth provides pipeline and regulatory timeline update
Feb 02FDA grants Hoth Therapeutics Pre-IND meeting for HT-001, shares up 15%
Jan 13Hoth Therapeutics to initiate IND enabling studies of HT-001 in cancer
Jan 11Hoth Therapeutics inks deal for treatment of multi-drug resistant bacterial lung infections, shares up 15%
Jan 04Revenue & Expenses Breakdown
How Hoth Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 0 | -8 | 5 | 3 |
30 Jun 24 | 0 | -7 | 5 | 3 |
31 Mar 24 | 0 | -8 | 5 | 3 |
31 Dec 23 | 0 | -8 | 4 | 3 |
30 Sep 23 | 0 | -10 | 5 | 4 |
30 Jun 23 | 0 | -10 | 5 | 5 |
31 Mar 23 | 0 | -11 | 6 | 5 |
31 Dec 22 | 0 | -11 | 6 | 5 |
30 Sep 22 | 0 | -11 | 6 | 5 |
30 Jun 22 | 0 | -12 | 5 | 6 |
31 Mar 22 | 0 | -13 | 6 | 7 |
31 Dec 21 | 0 | -14 | 7 | 8 |
30 Sep 21 | 0 | -12 | 6 | 6 |
30 Jun 21 | 0 | -10 | 6 | 4 |
31 Mar 21 | 0 | -10 | 6 | 4 |
31 Dec 20 | 0 | -7 | 4 | 3 |
30 Sep 20 | 0 | -10 | 7 | 4 |
30 Jun 20 | 0 | -10 | 6 | 4 |
31 Mar 20 | 0 | -9 | 5 | 3 |
31 Dec 19 | 0 | -8 | 5 | 2 |
30 Sep 19 | 0 | -4 | 3 | 1 |
30 Jun 19 | 0 | -3 | 2 | 1 |
31 Mar 19 | 0 | -3 | 2 | 1 |
31 Dec 18 | 0 | -2 | 1 | 1 |
30 Sep 18 | 0 | -3 | 2 | 1 |
Quality Earnings: HOTH is currently unprofitable.
Growing Profit Margin: HOTH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HOTH is unprofitable, and losses have increased over the past 5 years at a rate of 1.2% per year.
Accelerating Growth: Unable to compare HOTH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HOTH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: HOTH has a negative Return on Equity (-100.18%), as it is currently unprofitable.